Introduction
It is widely appreciated that the biomedical research literature accumulates at a rate far surpassing that at which anyone can read it, let alone assimilate it. It is shown here that, at the current rate, one would need to scan in excess of 130 journals and read in excess of 27 papers a day to keep up with the ®eld of Breast Cancer Genes, and the rate of accumulation of literature in this ®eld is still increasing.
Researchers have developed a variety of strategies to cope with an excessively large scienti®c literature. Traditionally, this has included books and review articles which summarize a large volume of primary literature. More recently, digital resources have provided additional solutions to this problem. Compared to books and reviews, digital resources can be more up-to-date, developed cumulatively, easier to use, and more powerful than their traditional predecessors. A wide variety of such resources are available to the breast cancer gene research community, ranging from repositories of primary data (e.g. sequence databases such as GenBank (Benson et al., 1999) , EMBL (Stoesser et al., 1999) , DDBJ (Tateno and Gojobori, 1997) , SwissProt (Bairoch and Apweiler, 1999) , and PIR (Barker et al., 1999) ) to resources for consumer health (e.g. OncoLink (Buhle et al., 1994) ). Described here is the Breast Cancer Gene Database (BCGD), an additional resource with unique bene®ts for breast cancer researchers. BCGD contains a comprehensive list of genes involved in breast cancer, and for each of these genes, information on a speci®c set of topics. Links to the literature reference for that information are provided. BCGD's organization by topic aords quick and convenient access to speci®c pieces of information. Finally, the World Wide Web (Web)-based interface for adding information and its collaborative capabilities will facilitate BCGD maintenance so that its value to the breast cancer gene community can remain high.
Results

Contents of BCGD
Because the facts in BCGD are extracted from the published literature, it is important to begin by identifying breast cancer gene publications. The PubMed database (http://www.ncbi.nlm.nih.gov/Entrez/medline.html) was searched for citations to these publications. (The database used by PubMed is a superset of the MEDLINE database; http:// www.ncbi.nlm.nih.gov/PubMed/overview.html.). A somewhat complicated search strategy, described in Materials and methods, was found to be necessary for the comprehensive retrieval of these citations. When this strategy was applied, citations to 90 373 publications were identi®ed. When the citations for each of the last 10 years was independently identi®ed (Figure 1) , it was found that the rate of accumulation of breast cancer gene publications is continuing to increase, and that in 1998, the rate of accumulation is equal to 27.4 publications a day.
As described in Materials and methods, making these searches reasonably complete required searching by gene, using all the names by which that gene is known. This approach has the added bene®t of providing a natural way to divide references among curators and to make the task of extracting data from these publications more manageable. The number of references retrieved from PubMed for each of the genes in BCGD is given in Table 1. BCGD is a`gene database' in that only the information pertaining to breast cancer and attributable to the characteristics or action of a particular gene is included in the database. Although the primary focus is on proto-oncogenes and tumor suppressor genes (genes implicated in the induction, maintenance or progression of breast cancer), genes that are of potential diagnostic or prognostic value or are of potential value in the treatment of cancer are also included. Proto-oncogenes and tumor suppressor genes are included in BCGD if they demonstrate one or more of the following (1) breast cancer-speci®c activation of transforming activity, e.g. in a DNA transfection assay; (2) a characteristic mutation or gene inactivation directly related to mammary gland carcinogenesis; (3) breast cancer speci®c, aberrant expression of a gene previously shown to be involved in oncogenesis; (4) loss of heterozygosity in human breast cancer not linked to adjacent genes. Unless augmented with further evidence for oncogenicity, genes that only manifest aberrant regulation in breast neoplasms are not included in the database. A listing of all genes in the database and their synonyms is given in Table 1 .
Information in the database consists of collections of Facts organized by Topic. Every fact in the database is linked to a journal citation. A list of Topics used in BCGD is shown in Table 2 . Although, as is discussed below, many Facts are duplicated, providing a complete listing of references relating to a given Fact was not attempted; the aim was to summarize the current state-of-knowledge of the ®eld not to provide a comprehensive list of published references.
BCGD currently contains approximately 2270 facts from 1162 publications describing 60 genes identi®ed as breast cancer genes. Most of these facts were obtained from PubMed abstracts, but 180 of them were obtained from the complete paper and thus represent facts that are not necessarily present in PubMed. BCGD curators used a combination of traditional browsing techniques and the PubMed search described above to identify publications from which to extract facts. The 2270 facts in BCGD have been extracted from 134 dierent journals.
Data entry
The Web-based data entry interface allows data to be entered into BCGD from anywhere in the world. Thus, the development of the database is envisioned to be a cooperative work of scientists, editors, curators and authors, regardless of their location. The feasibility of data entry has been demonstrated from multiple sites within the US and the Middle East. Access to the data entry forms is password protected and thus is available only to curators. Curators for BCGD and other tumor gene databases are actively being recruited; contact information is available at http://mbcr.bcm.tmc.edu/ermb/ authors.html.
Citations and their abstracts identi®ed by searching PubMed are automatically imported into BCGD and presented to the curators as an alphabetical list with the titles of articles as links to data entry forms. Using the Web-based data entry form (Figure 2 ), curators can enter information into the database, either from the Abstract or from a (separate) full text copy of the paper.
Editorial review
After a fact has been entered into the database, it is agged as`pending' and withheld from public view until one or more database editors have reviewed it. Upon review, such a fact can be¯agged as`reject', revise' or`publish'; only facts marked`publish' are available to appear in a search result. If a particular fact is found to be erroneously entered (even after it has been reviewed and published) the curator of that fact can alter it as required. The current editorial board of BCGD is listed at http://mbcr.bcm.tmc.edu/ermb/ bcgd/bcgd.html.
Data retrieval
BCGD is freely available via the Web. It is searchable in two ways; by gene name or by keyword. Information retrieved by a search using a gene name is organized into topical categories, e.g., gene regulation, DNA structure, protein size, function, etc ( Figure 3 ). Within each topic, information is presented as a list of`facts' plus an optional comment (when pertinent) along with the citation for the fact. Facts are brief statements of ®ndings, limited to 80 characters. All literature references in the database are hypertext links into PubMed and the query gene name appearing at the top of the page is a link into Online Mendelian Inheritance in Man (OMIM, http://www.ncbi.nlm.nih.gov/omim/).
Facts are often redundant; a particular fact, such as molecular weight or subcellular localization, may have been reported independently by dierent laboratories and as a result the fact is duplicated in BCGD with the duplicates having dierent citations. Presented this way, the viewer readily acquires a sense for the reproducibility of the given fact. Con¯icting data are often apparent in the fact lists. No eort is made to resolve such con¯icts, but rather they are left in for the viewer to judge. For example, the localization of BRCA1 to the nucleus was a well-known controversy for a year or so. The database fact listing for BRCA1 under the Topic`Cell location' variously lists the cytoplasm and secretory vesicles as well as the nucleus (not shown).
A common problem when attempting to use a gene name for queries of databases such as PubMed or GenBank is that genetics is plagued with , where #### is a number between 1989 and 1998, combined with the rest of the search using the AND Boolean operator synonyms, especially when a new ®eld is ®rst opening up. If one does not know all possible synonyms for a gene, it is very dicult to retrieve all papers pertaining to the gene. A signi®cant eort was made to include within BCGD as complete a synonym table as possible, allowing a user to query the database and retrieve all relevant facts using any one of the gene names. All words in the Fact and Comment ®elds of the database can be searched by Keyword. A Keyword search can be limited in scope to either the Fact or Comment ®eld, or it can be limited to only certain Topics in order to increase the speci®city of the search result. For example, one could search with the keyword transcription' and limit the search to the`Biochemical type'. The result of this search will be a list of genes which is a good approximation of all transcription factors (Figure 4) . Currently, searches with multiple keywords are treated as a logical`OR'. In other words, a keyword search with`receptor kinase' will ®nd all entries with either`receptor' or`kinase' in the fact or comment ®elds.
Discussion
Given the wide variety of traditional and digital resources available to the breast cancer researcher, what additional bene®ts can be derived from BCGD? Despite the fact that it is heavily based on PubMed, a researcher would not be able to extract the information in BCGD from PubMed without duplicating the many hours of work performed by BCGD curators. By identifying the genes which are breast cancer genes, by identifying the synonyms by which each gene is known, by collecting all the information about each gene in one place, and by organizing it by topic, BCGD's curators make information available that is practically inaccessible in PubMed. (An analogous comparison is between a dictionary and a book containing the same words and de®nitions in random order). In addition, data extracted from papers rather than abstracts will frequently be absent from its PubMed citation.
OMIM is the resource that probably has greater overlap with BCGD than any other. It is possible to search OMIM with the words`Breast Cancer' and retrieve a list of 148 records, where most records correspond to a gene. This list of genes is not a reliable list of breast cancer genes (nor was it intended by the developers of OMIM to be) and the data in the records for the breast cancer genes (which for the most part are in OMIM) focus more on human genetic disease than on cancer, and may or may not contain information critical to the breast cancer gene researcher; whether a gene encodes a tyrosine kinase, a receptor, or a transcription factor, for example.
LocusLink (http://www.ncbi.nlm.nih.gov/ LocusLink/); GeneCards (Rebhan et al., 1998), and HUGO (http://ash.gene.ucl.ac.uk/nomenclature/) are extremely useful resources that are similar one to another. These consist largely of links to various information resources, and in addition contain a small amount of direct information about the gene. Neither of them provide a list of breast cancer genes nor are they intended to provide the breadth and depth of information being collected in BCGD. (Table 2 ) and entering the brief statement of fact and longer comments where required. In addition, the curator can indicate the source of the fact (see the legend to Figure 3 ) and the status of the fact (e.g. Published, Pending, On Hold. Described in Results.) After a Fact is entered, the curator may elect to enter another Fact from the same paper, go on to the next paper, or return to a list of all available papers. A link provides access to Facts previously entered by any of the curators so that duplicate entries can be avoided. (In this and the next three ®gures, the browser's (Netscape's) navigation tools have been hidden) CGAP (Kuska, 1996 ) is an extremely important project whose goal is to characterize the changing expression of a large number of genes as normal cells develop into tumor cells. It is more of a research project than an information resource. There is very little overlap between BCGD and CGAP; both are important to breast cancer researchers. Similarly, the Breast Cancer Information Core (BIC, http:// www.nhgri.nih.gov/ Intramural_research/ Lab_transfer/ Bic/) is a specialized database of published and unpublished data on germline mutations in a few breast cancer genes and has little overlap with BCGD.
Biology of the Mammary Gland (http://mammary.nih.gov/) is a website that collects a variety of kinds of information of interest to mammary gland researchers, much of which will be valuable to breast cancer researchers. Some of this information concerns identi®cation of and sources for important reagents (e.g. transgenic mice) which overlaps little with BCGD. In addition, this site contains a number of reviews, some of which overlap in content with BCGD. These represent more or less traditional reviews and as such are selective rather than comprehensive and are intended primarily to educate rather than being compendia of data. Thus, in a practical sense, these also overlap little with BCGD.
In summary, BCGD provides a resource of unique value to the breast cancer researcher with minimal overlap with other existing resources.
BCGD is an extension of a larger, earlier database called the Tumor Gene Database (http:// mbcr.bcm.tmc.edu/ermb/tgdb/tgdb.html) which covers The fraction of mutation carriers that will develop a tumor 44% at risk of breast cancer by age 70 Tumor Type
The kinds of tumors that result from mutations of the gene Lymphoma a As the ®eld changes new topics can be added and old ones abandoned. New facts cannot be added to abandoned topics but facts still appear under those topics in query reports. This table contains only current topics approximately 350 tumor genes. There are plans to create a prostate and colon-speci®c extensions of TGDB as well. TGDB is structured to allow sharing of information among the databases in cases where a given gene can be involved in more than one type of cancer (the majority of cases). In other words, Facts about p53 entered into the database by a curator interested in, for example, prostate cancer, will be visible to a user searching BCGD for p53 Facts, since the gene is common to both cancers. Thus, the BCGD paradigm has the potential to bene®t research into other forms of cancer and will help researchers working on dierent cancers to eectively share their results.
BCGD oers both short and long term bene®ts to the breast cancer gene research community. Currently, the database contains a reasonably comprehensive list of the genes which have been shown with some certainty to be important in Breast Cancer, the various names given to each of these genes, and a useful collection of basic facts about these genes; subcellular location, size, biochemical activity, and so forth. Further, The mechanisms for collaborative curation of a gene or set of genes by researchers throughout the world, the mechanisms for editorial oversight by experts in the ®eld (capabilities unique among biological databases of this type) will facilitate its maintenance.
In the long-term, maximizing the rate of scienti®c progress will require continuing improvement in the methods for disseminating and retrieving results obtained. To that end, BCGD is structured to accommodate future development. Currently, BCGD supports hypertext links to OMIM and PubMed. Future versions of the database should provide direct links to other appropriate biological resources such as GenBank, 3-Dimensional protein or DNA structure Databases mainly NCBI's Molecular Modeling Database (Ohkawa et al., 1995) , and the Mouse Genome Database (Blake et al., 1999) . Finally, BCGD and other similar databases can be used as a platform for the deposition of primary unpublished data in much Figure 3 Result of a Gene search using MDM2 as query. The Gene name is listed at the top of the page along with relevant synonyms. Individual facts are listed below, organized by Topic. Facts pertaining to Cell Location and Cell Type Distribution are visible in this ®gure. Each Fact entry includes a brief statement of the fact (bold face lettering), longer comments explicating the Fact where required, a link to the reference for the Fact and the curator's initials in square brackets. The individual Facts originate from a variety of sources. The fact may be taken from a primary research paper, from the PubMed abstract of a primary research paper, or from a review. The primary report for the fact might be the cited paper, or the cited paper might report the fact as coming from one of its references. The source for each Fact is indicated by the following icons: double gold stars, primary Fact from a full text paper; single gold star, primary fact from an abstract; red dot,`secondary' Fact (i.e. the cited paper mentions the fact but cites one of its references as the source of that fact) from a full paper; blue dot, secondary Fact from an abstract; red star, primary fact from a Review; blue star, secondary fact from a review; no symbol, source unknown (e.g. an older fact). Primary facts are, of course, rare or absent from most reviews the same way that DNA sequence is frequently entered directly into Genbank in the absence of conventional publication. For this application, the editorial functions built in to the system could be used to ensure adequate peer review of information published this way.
Materials and methods
Identi®cation of citations using PubMed
The goal of the Breast Cancer Gene Database is to contain a complete description of all of the genes which identi®ed as tumor genes involved in breast cancer. An important tool towards reaching that goal is a strategy for identifying all of the papers published on these genes. Development of a sensitive and selective search strategy for PubMed citations relevant to tumor genes has been a signi®cant eort, is ongoing, and will be described more fully elsewhere. The current best strategy for identi®cation of all such publications, referred to as the`high stringency search', is:
Approximately 95% of the references retrieved by this search are relevant to tumor genes and it retrieves approximately 50% of the relevant references in PubMed. Restricting this list to those citations relevant to breast cancer genes requires a two part strategy. The ®rst part of that strategy combines the above search with:`B reast Neoplasms'' [MESH TERMS] using the AND Boolean operator. This initial search misses many references which concern a Breast Cancer Gene, but which report results which themselves are not particular to Breast Cancer. Thus, this initial search is used primarily to develop and maintain the list of Breast Cancer genes. Thereafter, facts about individual genes are searched for by name using the search: Figure 4 Result of a keyword search using receptor as the query term. The result of a keyword search organizes Facts ®rst by Gene Name, and then by Topic within a gene. This example shows the result of a search for the keyword`Transcription' in the Fact or Comment ®elds limited to the Topic`Biochemical Type'. This generates a list of genes mostly consisting of and containing most of the breast cancer genes that are transcription factors
GeneName [WORD]
This search needs to be repeated for each of the names by which the gene is known (e.g. H-ras, Hras, Ha-ras, rasH, etc.). For some of these names, a large number of irrelevant citations are retrieved, e.g. because the gene name rasH matches the medically common word rash. These can be eliminated by using the Boolean AND term to combine the gene name search with a tumor gene speci®c search. Using the`high stringency search', described above, has the disadvantage of eliminating half the relevant citations. To reduce that eect, a`low stringency search' was developed which by itself is not very useful in that only 25% of the citations retrieved are relevant to tumor genes, but when combined with a gene name returns about 75% of the relevant papers. This strategy is: 
